Clinical Drug Investigation

, Volume 10, Issue 1, pp 53–58 | Cite as

Cost-Containment in CAPD Patients with Ultrafiltration Failure

  • E. M. Peers
  • A. C. Scrimgeour
  • A. R. Haycox
Outcomes Research


Continuous ambulatory peritoneal dialysis (CAPD) using glucose-based solutions is used increasingly to treat patients with renal failure. Ultrafiltration failure occurs in CAPD patients after a variable time; the number of CAPD patients with ultrafiltration failure is therefore rising; this presents a situation which could overwhelm the present United Kingdom haemodialysis resources. Icodextrin 7.5% is a new glucose-polymer-based CAPD solution best suited to the long dwell times that present the greatest challenge to patients with ultra-filtration failure. The icodextrin compassionate-use programme was set up to allow CAPD patients access to icodextrin before commercial availability. There was no rigid protocol; patients with ultrafiltration failure received icodextrin (1.5 or 2L) for the long dwell for as long as it was beneficial. The outcome of the programme was analysed by life-table analysis for (a) overall technique survival in all ultrafiltration failure patients in the programme, and (b) CAPD extension time in patients who either stayed in the programme or left it because of worsening ultrafiltration failure. 56 ultrafiltration failure patients were included in the programme. In this group, life-table analysis showed a technique survival of 38% after 1 year. Withdrawals were: 6 transplants, 6 deaths and 23 transfers to haemodialysis. For CAPD extension time due to icodextrin, 36 patients were included: life-table analysis showed that 60% remained on CAPD 12 months after starting icodextrin treatment. Overall, in patients with ultrafiltration failure, the inclusion of icodextrin in the dialysis prescription extended CAPD lifetime by an average of at least 1 year. At current United Kingdom costs, CAPD with the inclusion of icodextrin represents a cost saving of approximately £1500 per annum over hospital-based haemodialysis, as well as the benefit to the patient of remaining on the chosen modality of treatment.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Mallick NR London renal review. HMSO, London 1993Google Scholar
  2. 2.
    Geerlings W, Tufveson G, Enrich JHH, et al. Report on management of renal failure in Europe, XXIII. Nephrol Dial Transplant 1994; 1: 6–25Google Scholar
  3. 3.
    Brunner FP, Tufveson G, Geerlings W, et al. Combined report on regular dialysis and transplantation in Europe XXI 1990. Nephrol Dial Transplant 1991; 6 Suppl. 4: 1–29PubMedGoogle Scholar
  4. 4.
    Dobbie JW. New concepts in molecular biology and ultrastructural pathology of the peritoneum: their significance for peritoneal dialysis. Am J Kidney Dis 1990; 15: 97–109PubMedGoogle Scholar
  5. 5.
    Alsop RM. History, chemical and pharmaceutical development of icodextrin. Perit Dial Int 1994; 14 Suppl. 2: S5–S12Google Scholar
  6. 6.
    Mistry CD, Mallick NP, Gokal R. Ultrafiltration with an isosmotic solution during long peritoneal dialysis exchanges. Lancet 1987; 2: 178–82PubMedCrossRefGoogle Scholar
  7. 7.
    Mistry CD, Gokal R, Peers EM, et al. A randomised multicentre clinical trial comparing isomolar icodextrin with hyperosmolar glucose solutions in CAPD: a six-month study. Kidney Int 1994; 46: 496–503PubMedCrossRefGoogle Scholar
  8. 8.
    Armitage P, Berry G. Statistical methods in medical research. 2nd ed. Oxford: Blackwell, 1987: Chapter 14: 421–39Google Scholar
  9. 9.
    Hain H, Kessel M. Aspects of new solutions for peritoneal dialysis. Nephrol Dial Transplant 1987; 2: 67–72PubMedGoogle Scholar
  10. 10.
    Haycox A, Krupa R. The cost effectiveness of renal provision in the UK. Medeconomics. In pressGoogle Scholar
  11. 11.
    Published basic National Health Service price and published hospital price list.Google Scholar

Copyright information

© Adis International Limited 1995

Authors and Affiliations

  • E. M. Peers
    • 1
  • A. C. Scrimgeour
    • 1
  • A. R. Haycox
    • 2
  1. 1.ML Laboratories plcSt Albans, HertfordshireEngland
  2. 2.Department of Pharmacy Policy and PracticeKeele UniversityKeele, StaffordshireEngland

Personalised recommendations